AgomAb Therapeutics (NASDAQ:AGMB) Stock: Insider Tim Jasper Knotnerus Acquires 6,000 Shares

AgomAb Therapeutics NV (NASDAQ:AGMB) CEO Tim Jasper Knotnerus acquired 6,000 shares of the stock in a transaction dated Monday, October 5th. The stock was acquired at an average cost of $8.48 per share, with a total value of $50,880.00. Following the transaction, the chief executive officer directly owned 16,823 shares in the company, valued at approximately $142,659.04. This represents a 55.44% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Tim Jasper Knotnerus also recently made the following trade(s):

• On Tuesday, October 6th, Tim Jasper Knotnerus bought 5,000 shares of AgomAb Therapeutics stock. The shares were acquired at an average cost of $8.70 per share, for a total transaction of $43,500.00.

AgomAb Therapeutics Trading Up 1.7%

AgomAb Therapeutics stock opened at $8.84 on Wednesday. The stock has a 50-day moving average of $12.82 and a two-hundred day moving average of $12.00. AgomAb Therapeutics NV has a one year low of $7.97 and a one year high of $17.82.

AgomAb Therapeutics (NASDAQ:AGMB) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.46) earnings per share for the quarter. As a group, sell-side analysts forecast that AgomAb Therapeutics NV will post -1.76 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on AGMB. B. Riley Financial assumed coverage on shares of AgomAb Therapeutics in a research note on Thursday, July 23rd. They set a “buy” rating and a $34.00 price target on the stock. Piper Sandler initiated coverage on shares of AgomAb Therapeutics in a research note on Tuesday, August 25th. They set an “overweight” rating and a $60.00 price objective for the company. Wall Street Zen lowered shares of AgomAb Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, September 27th. HC Wainwright reissued a “buy” rating on shares of AgomAb Therapeutics in a research report on Wednesday, September 16th. Finally, Cantor Fitzgerald assumed coverage on AgomAb Therapeutics in a research note on Wednesday, August 19th. They issued an “overweight” rating for the company. Seven investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.50.

About AgomAb Therapeutics

Agomab Therapeutics N.V. is a clinical-stage biotechnology company developing antibody-based medicines designed to activate biological pathways involved in tissue repair and regeneration. The company focuses on serious diseases in which restoring or rebuilding damaged tissue could provide therapeutic benefit.

Agomab’s lead program, AGMB-129, is an investigational, gut-restricted agonist of fibroblast growth factor receptor 1c (FGFR1c) being developed for inflammatory bowel disease, including Crohn’s disease.